Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection

Inclusion Criteria

• Be willing and able to provide written informed consent for the study.
• Subject has accepted radical hepatic resection, and preoperative imaging is no vascular invasion.
• Postoperative pathology confirmed Hepatocellular carcinoma with negative margin and microvascular invasion (MVI).
• Age between 18-75 years old.
• Radiology confirmed complete response (CR) after radical surgery.
• Child-Pugh A.
• Eastern Cooperative Oncology Group(ECOG) body condition score 0.
• Adequate hepatic and renal function:

Hemoglobin ≥ 9.0g/dl. Absolute neutrophil count (ANC) > 1,500/mm3. Platelets ≥ 50,000/ul. Total bilirubin (TBIL) ≤ 2mg/dl. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5 the upper limit of normal (ULN) for the institution.

Alkaline phosphatase (ALP) ≤ 4 the upper limit of ULN. Prothrombin time (PT) > 50% or prothrombin time-international normalized ratio (PT-INR) 2.

• Epilepsy requiring steroid or antiepileptic drugs.
• History of allotransplantation.
• History or any evidence of hemorrhage.
• Subjects undergoing renal dialysis.
• Pregnancy or breast-feeding.
• Prior or undergoing cancers that primary sites are different from the carcinoma of this study. Exceptions to this are:

Cervical carcinoma in situ (CIS) Cured basal cell carcinoma Superficial bladder tumor Cured cancers over 3 years before the study

• Uncontrolled Ascites by diuretic treatment.
• History of encephalopathy.
• Gastrointestinal hemorrhage in 30 days before the study.
• History of esophageal variceal hemorrhage and it is no effective treatment to prevent the recurrence of hemorrhage.
• Major surgery except radical hepatic resection was performed in 4 weeks before the study.
• Autologous bone marrow transplantation (ABMT) in 4 weeks before the study.
• Concurrent treatment on another clinical trial or treatment on another clinical trial in 4 weeks before the study.
• Drug abuse, medical treatment, mental illness or social disorders that would interfere with subjects' participation, or confound the results of the trial.
• Any condition that would interfere with or endanger the safety and compliance of subjects.